{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:14:42Z","timestamp":1766182482709,"version":"3.37.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Preservation of visual acuity remains a challenging issue after globe sparing therapy of large uveal melanoma. The aim of our study was analyzing the functional outcome after brachytherapy with bi-nuclide plaques (BBNP), maintaining prognostic factors for legal blindness (LB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We have analyzed all consecutive patients with large uveal melanoma treated with BBNP at our institution between 01\/1999 and 12\/2020. The post-treatment follow-up data were screened up to 06\/2023. Univariate and multivariate Cox regression analysis was performed to identify predictive factors for development of LB following BBNP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 570 patients with median age of 65.6 years (interquartile range [IQR]: 54.5\u201374.0) underwent BBNP. During the median post-treatment follow-up of 30.8 months (IQR: 12.9\u201357.3), LB was diagnosed in 287 (50.4%) patients. Patients\u2019 age (&gt;\u200967 years, adjusted hazard ratio [aHR]\u2009=\u20091.58, 95%-confidence interval [CI]\u2009=\u20091.24\u20132.00, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), tumor thickness (&gt;\u20098.5\u00a0mm, aHR\u2009=\u20091.43, 95%-CI\u2009=\u20091.12\u20131.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), VA (&gt;\u20090.5 LogMAR, aHR\u2009=\u20091.59, 95%-CI\u2009=\u20091.25\u20132.02, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and ciliary body involvement (aHR\u2009=\u20090.77, 95%-CI\u2009=\u20090.60\u20130.97, <jats:italic>p<\/jats:italic>\u2009=\u20090.029) were confirmed as independent predictors of LB in the final multivariable Cox regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Approximately a half of patients with large uveal melanoma develop LB around 2.5 years after brachytherapy. Further optimization of treatment strategies, including both therapeutic and preventive measures, has the potential to enhance the functional outcome after episcleral plaque therapy for large UMs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13014-024-02576-6","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T20:48:16Z","timestamp":1739393296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional outcome after Brachytherapy with bi-nuclide (Ru-106\/Iodine-125) plaques in large uveal melanomas"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-5077","authenticated-orcid":false,"given":"Leyla","family":"Jabbarli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miltiadis","family":"Fiorentzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Rating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boerge","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Biewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Fl\u00fchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Bornfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Sauerwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos E.","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2576_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.preteyeres.2018.03.004","volume":"66","author":"B Damato","year":"2018","unstructured":"Damato B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death - A personal view. Prog Retin Eye Res. 2018;66:187\u201399. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.03.004.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"2576_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31(2):241\u201357. https:\/\/doi.org\/10.1038\/eye.2016.275.","journal-title":"Eye"},{"issue":"11","key":"2576_CR3","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0161-6420(03)00661-4","volume":"110","author":"I Puusaari","year":"2003","unstructured":"Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivela T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223\u201334. https:\/\/doi.org\/10.1016\/S0161-6420(03)00661-4.","journal-title":"Ophthalmology"},{"issue":"10","key":"2576_CR4","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/s0161-6420(02)01181-8","volume":"109","author":"CL Shields","year":"2002","unstructured":"Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (>\u2009or =\u20098-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838\u201349. https:\/\/doi.org\/10.1016\/s0161-6420(02)01181-8.","journal-title":"Ophthalmology"},{"issue":"10","key":"2576_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0161-6420(02)01273-3","volume":"109","author":"NE Bechrakis","year":"2002","unstructured":"Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology. 2002;109(10):1855\u201361.","journal-title":"Ophthalmology"},{"key":"2576_CR6","doi-asserted-by":"publisher","unstructured":"Guberina M, Sokolenko E, Guberina N, Dalbah S, Pottgen C, Lubcke W, et al. Feasibility, method and early outcome of image-guided Volumetric Modulated Arc Radiosurgery followed by Resection for AJCC Stage IIA-IIIB High-Risk large intraocular melanoma. Cancers (Basel). 2022;14(19). https:\/\/doi.org\/10.3390\/cancers14194729.","DOI":"10.3390\/cancers14194729"},{"issue":"3","key":"2576_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.survophthal.2020.08.007","volume":"66","author":"M Fallico","year":"2021","unstructured":"Fallico M, Chronopoulos A, Schutz JS, Reibaldi M. Treatment of radiation maculopathy and radiation-induced macular edema: a systematic review. Surv Ophthalmol. 2021;66(3):441\u201360. https:\/\/doi.org\/10.1016\/j.survophthal.2020.08.007.","journal-title":"Surv Ophthalmol"},{"key":"2576_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejmp.2022.08.001","volume":"101","author":"C Oare","year":"2022","unstructured":"Oare C, Sun S, Dusenbery K, Reynolds M, Koozekanani D, Gerbi B, et al. Analysis of dose to the macula, optic disc, and lens in relation to vision toxicities - a retrospective study using COMS eye plaques. Phys Med. 2022;101:71\u20138. https:\/\/doi.org\/10.1016\/j.ejmp.2022.08.001.","journal-title":"Phys Med"},{"issue":"2","key":"2576_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/s0161-6420(00)00526-1","volume":"108","author":"BM Melia","year":"2001","unstructured":"Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report 16. Ophthalmology. 2001;108(2):348\u201366. https:\/\/doi.org\/10.1016\/s0161-6420(00)00526-1.","journal-title":"Ophthalmology"},{"issue":"2","key":"2576_CR10","doi-asserted-by":"publisher","first-page":"100869","DOI":"10.1016\/j.adro.2021.100869","volume":"7","author":"WJ Kheir","year":"2022","unstructured":"Kheir WJ, Stinnett SS, Meltsner S, Semenova E, Mowery YM, Craciunescu O, et al. Preliminary results of uveal melanoma treated with Iodine-125 plaques: analysis of Disease Control and visual outcomes with 63 gy to the Target volume. Adv Radiat Oncol. 2022;7(2):100869. https:\/\/doi.org\/10.1016\/j.adro.2021.100869.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2576_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ijrobp.2009.08.059","volume":"78","author":"PA Saconn","year":"2010","unstructured":"Saconn PA, Gee CJ, Greven CM, McCoy TP, Ekstrand KE, Greven KM. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study. Int J Radiat Oncol Biol Phys. 2010;78(3):844\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2576_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41433-022-01944-4","volume":"37","author":"RFJ O\u2019Day","year":"2023","unstructured":"O\u2019Day RFJ, Roelofs KA, Negretti GS, Hay G, Arora AK, Stoker I, et al. Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma. Eye. 2023;37(5):959\u201365. https:\/\/doi.org\/10.1038\/s41433-022-01944-4.","journal-title":"Eye"},{"issue":"2","key":"2576_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijrobp.2005.02.059","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63(2):392\u2013400. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.02.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2576_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jamaophthalmol.2016.0104","volume":"134","author":"HA Aziz","year":"2016","unstructured":"Aziz HA, Singh N, Bena J, Wilkinson A, Singh AD. Vision loss following Episcleral Brachytherapy for Uveal Melanoma: development of a Vision Prognostication Tool. JAMA Ophthalmol. 2016;134(6):615\u201320. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.0104.","journal-title":"JAMA Ophthalmol"},{"key":"2576_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13928","author":"L Jabbarli","year":"2021","unstructured":"Jabbarli L, Guberina M, Biewald E, Fluhs D, Guberina N, Le Guin CHD, et al. Scleral necrosis after brachytherapy for uveal melanoma: analysis of risk factors. Clin Exp Ophthalmol. 2021. https:\/\/doi.org\/10.1111\/ceo.13928.","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"2576_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1118\/1.1755471","volume":"31","author":"D Fluhs","year":"2004","unstructured":"Fluhs D, Anastassiou G, Wening J, Sauerwein W, Bornfeld N. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med Phys. 2004;31(6):1481\u20138. https:\/\/doi.org\/10.1118\/1.1755471.","journal-title":"Med Phys"},{"key":"2576_CR17","volume-title":"Radioonkologie Band 2: Klinik","author":"W Sauerwein","year":"2009","unstructured":"Sauerwein W, Stannard CE. Auge Und Orbita. In: Bamberg M, Molls M, Sack H, Zuckschwerdt, editors. Radioonkologie Band 2: Klinik. M\u00fcnchen Wien New York: W.; 2009."},{"key":"2576_CR18","unstructured":"Version:2019 I-. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version 2019. https:\/\/icd.who.int\/browse10\/2019\/en#\/H54 (2019). Accessed."},{"issue":"5","key":"2576_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/bjophthalmol-2019-314686","volume":"104","author":"LA Dalvin","year":"2020","unstructured":"Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, et al. Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients. Br J Ophthalmol. 2020;104(5):697\u2013702. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314686.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2576_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brachy.2015.09.013","volume":"15","author":"CE Wisely","year":"2016","unstructured":"Wisely CE, Hadziahmetovic M, Reem RE, Hade EM, Nag S, Davidorf FH, et al. Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy. Brachytherapy. 2016;15(1):12\u201322. https:\/\/doi.org\/10.1016\/j.brachy.2015.09.013.","journal-title":"Brachytherapy"},{"issue":"11","key":"2576_CR21","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/s41433-022-02316-8","volume":"37","author":"E Asplund","year":"2023","unstructured":"Asplund E, Fili M, Pansell T, Brautaset R, Nilsson M, Stalhammar G. The prognostic implication of visual acuity at the time of uveal melanoma diagnosis. Eye. 2023;37(11):2204\u201311. https:\/\/doi.org\/10.1038\/s41433-022-02316-8.","journal-title":"Eye"},{"issue":"3","key":"2576_CR22","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.adro.2022.101152","volume":"8","author":"R Kal Omar","year":"2023","unstructured":"Kal Omar R, Hagstrom A, Dahlander S, Carlsson Tedgren A, Stalhammar G. A prognostic score for the prediction of Local Treatment Failure in Plaque Brachytherapy of Uveal Melanoma. Adv Radiat Oncol. 2023;8(3):101152. https:\/\/doi.org\/10.1016\/j.adro.2022.101152.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"2576_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1159\/000495249","volume":"5","author":"BA King","year":"2019","unstructured":"King BA, Awh C, Gao BT, Wang J, Kocak M, Morales-Tirado VM, et al. Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 posterior uveal melanoma: clinical outcomes in 158 patients. Ocular Oncol Pathol. 2019;5(5):340\u20139. https:\/\/doi.org\/10.1159\/000495249.","journal-title":"Ocular Oncol Pathol"},{"issue":"9","key":"2576_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","volume":"118","author":"CL Shields","year":"2000","unstructured":"Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219\u201328. https:\/\/doi.org\/10.1001\/archopht.118.9.1219.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"2576_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/ceo.13758","volume":"48","author":"X Yang","year":"2020","unstructured":"Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, et al. Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients. Clin Exp Ophthalmol. 2020;48(5):610\u201323. https:\/\/doi.org\/10.1111\/ceo.13758.","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"2576_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.21873\/invivo.11784","volume":"34","author":"MM Pagliara","year":"2020","unstructured":"Pagliara MM, Tagliaferri L, Lenkowicz J, Azario L, Giattini D, Fionda B, et al. AVATAR: analysis for visual acuity prediction after Eye Interventional Radiotherapy. Vivo. 2020;34(1):381\u20137. https:\/\/doi.org\/10.21873\/invivo.11784.","journal-title":"Vivo"},{"key":"2576_CR27","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.2147\/OPTH.S433531","volume":"17","author":"AA Victor","year":"2023","unstructured":"Victor AA, Andayani G, Djatikusumo A, Yudantha AR, Hutapea MM, Gunardi TH, et al. Efficacy of prophylactic Anti-VEGF in preventing Radiation Retinopathy: a systematic review and Meta-analysis. Clin Ophthalmol. 2023;17:2997\u20133009. https:\/\/doi.org\/10.2147\/OPTH.S433531.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"2576_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5114\/jcb.2018.77955","volume":"10","author":"D Miguel","year":"2018","unstructured":"Miguel D, de Frutos-Baraja JM, Lopez-Lara F, Saornil MA, Garcia-Alvarez C, Alonso P, et al. Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. J Contemp Brachytherapy. 2018;10(4):347\u201359. https:\/\/doi.org\/10.5114\/jcb.2018.77955.","journal-title":"J Contemp Brachytherapy"},{"key":"2576_CR29","doi-asserted-by":"publisher","DOI":"10.1055\/a-2275-5575","author":"F Lalos","year":"2024","unstructured":"Lalos F, Fluhs D, Guberina M, Bornfeld N, Stuschke M, Sauerwein W, et al. Treatment-related complications and functional results after Ruthenium-106 brachytherapy in small to medium size Uveal Melanomas (Part 2). Klin Monatsbl Augenheilkd. 2024. https:\/\/doi.org\/10.1055\/a-2275-5575.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"2576_CR30","doi-asserted-by":"publisher","DOI":"10.1055\/a-2268-0985","author":"F Lalos","year":"2024","unstructured":"Lalos F, Fluhs D, Guberina M, Bornfeld N, Stuschke M, Sauerwein W, et al. Tumor- and Radiation-related complications after Ruthenium-106 brachytherapy in small to medium uveal melanomas (part 1). Klin Monatsbl Augenheilkd. 2024. https:\/\/doi.org\/10.1055\/a-2268-0985.","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"4","key":"2576_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ajo.2009.11.006","volume":"149","author":"PT Finger","year":"2010","unstructured":"Finger PT, Chin KJ, Yu GP. Palladium-103 for Choroidal Melanoma Study G. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010;149(4):608\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2009.11.006.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2576_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.brachy.2018.07.002","volume":"17","author":"BHA Le","year":"2018","unstructured":"Le BHA, Kim JW, Deng H, Rayess N, Jennelle RL, Zhou SY, et al. Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review. Brachytherapy. 2018;17(6):981\u20139. https:\/\/doi.org\/10.1016\/j.brachy.2018.07.002.","journal-title":"Brachytherapy"},{"issue":"5","key":"2576_CR33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41433-022-02200-5","volume":"37","author":"BE Powell","year":"2023","unstructured":"Powell BE, Chin KJ, Finger PT. Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned. Eye. 2023;37(5):866\u201374. https:\/\/doi.org\/10.1038\/s41433-022-02200-5.","journal-title":"Eye"},{"issue":"12","key":"2576_CR34","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/bjophthalmol-2017-310315","volume":"101","author":"RI Kaplan","year":"2017","unstructured":"Kaplan RI, Chaugule SS, Finger PT. Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab. Br J Ophthalmol. 2017;101(12):1694\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310315.","journal-title":"Br J Ophthalmol"},{"key":"2576_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003483","author":"L Jabbarli","year":"2024","unstructured":"Jabbarli L, Biewald E, Guberina M, Le Guin CHD, Thomasen H, Fiorentzis M, et al. Surgical Outcome after treatment of Radiation-Induced Scleral necrosis in patients with Uveal Melanoma. Cornea. 2024. https:\/\/doi.org\/10.1097\/ICO.0000000000003483.","journal-title":"Cornea"},{"issue":"2","key":"2576_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","volume":"138","author":"CL Shields","year":"2020","unstructured":"Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, et al. Visual outcome at 4 years following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (every 4 months for 2 years) for Uveal Melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 2020;138(2):136\u201346. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5132.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"2576_CR37","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00417-016-3485-9","volume":"254","author":"M Kamrava","year":"2016","unstructured":"McCannel TA, Kamrava M, Demanes J, Lamb J, Bartlett JD, Almanzor R, et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. Graefe\u2019s Archive Clin Experimental Ophthalmol = Albrecht Von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie. 2016;254(12):2461\u20137. https:\/\/doi.org\/10.1007\/s00417-016-3485-9.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol = Albrecht Von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie"},{"issue":"7","key":"2576_CR38","doi-asserted-by":"publisher","first-page":"e5270","DOI":"10.7759\/cureus.5270","volume":"11","author":"LJ Lyons","year":"2019","unstructured":"Lyons LJ, Hinds ED, Chexal S, Berger B. Silicone oil and Iodine-125 brachytherapy for Uveal Melanoma in High-Risk patients. Cureus. 2019;11(7):e5270. https:\/\/doi.org\/10.7759\/cureus.5270.","journal-title":"Cureus"},{"issue":"7","key":"2576_CR39","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/archophthalmol.2010.117","volume":"128","author":"SC Oliver","year":"2010","unstructured":"Oliver SC, Leu MY, DeMarco JJ, Chow PE, Lee SP, McCannel TA. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma. Arch Ophthalmol. 2010;128(7):888\u201393. https:\/\/doi.org\/10.1001\/archophthalmol.2010.117.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"2576_CR40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/eye.2012.158","volume":"26","author":"Y Ahuja","year":"2012","unstructured":"Ahuja Y, Kapoor KG, Thomson RM, Furutani KM, Shultz RW, Stafford SL, et al. The effects of intraocular silicone oil placement prior to iodine 125 brachytherapy for uveal melanoma: a clinical case series. Eye. 2012;26(11):1487\u20139. https:\/\/doi.org\/10.1038\/eye.2012.158.","journal-title":"Eye"},{"issue":"2","key":"2576_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijrobp.2014.02.021","volume":"89","author":"TA McCannel","year":"2014","unstructured":"McCannel TA, McCannel CA. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series. Int J Radiat Oncol Biol Phys. 2014;89(2):347\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.02.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2576_CR42","doi-asserted-by":"publisher","unstructured":"Jarczak J, Karska-Basta I, Romanowska-Dixon B. Deterioration of visual acuity after Brachytherapy and Proton Therapy of Uveal Melanoma, and methods of counteracting this complication based on recent publications. Med (Kaunas). 2023;59(6). https:\/\/doi.org\/10.3390\/medicina59061131.","DOI":"10.3390\/medicina59061131"},{"issue":"1","key":"2576_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5114\/jcb.2016.57818","volume":"8","author":"M Naseripour","year":"2016","unstructured":"Naseripour M, Jaberi R, Sedaghat A, Azma Z, Nojomi M, Falavarjani KG, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8(1):66\u201373. https:\/\/doi.org\/10.5114\/jcb.2016.57818.","journal-title":"J Contemp Brachytherapy"},{"issue":"9","key":"2576_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bjo.2009.157701","volume":"93","author":"N Kaiserman","year":"2009","unstructured":"Kaiserman N, Kaiserman I, Hendler K, Frenkel S, Pe\u2019er J. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas. Br J Ophthalmol. 2009;93(9):1167\u201371. https:\/\/doi.org\/10.1136\/bjo.2009.157701.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2576_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijrobp.2014.01.026","volume":"89","author":"BA Perez","year":"2014","unstructured":"Perez BA, Mettu P, Vajzovic L, Rivera D, Alkaissi A, Steffey BA, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Int J Radiat Oncol Biol Phys. 2014;89(1):127\u201336. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.026.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02576-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:53:44Z","timestamp":1739462024000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02576-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02576-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"type":"electronic","value":"1748-717X"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Ethics Committee (Medical faculty of the University Duisburg-Essen, registration number 20-9165-BO). All patients signed the informed consent within the written treatment contract on admission. The Study was registered in the German clinical trial registry (DRKS, Unique identifier: DRKS00019049, registration date 10.21.2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}